HouseH.R. 10649119th Congress
Safe Disposal of Opioids Act of 2026
Full Text
Official text as published. Use Ctrl+F / Cmd+F to search within the document.
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 10649 Introduced in House (IH)]
<DOC>
119th CONGRESS
2d Session
H. R. 10649
To amend the Comprehensive Addiction and Recovery Act of 2016 to
authorize the Attorney General, in coordination with the Administrator
of the Drug Enforcement Administration, the Secretary of Health and
Human Services, and the Director of the Office of National Drug Control
Policy, to award grants to covered entities to establish or maintain
disposal sites for unwanted prescription medications, and for other
purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
October 1, 2026
Ms. Bonamici (for herself and Mr. Moore of West Virginia) introduced
the following bill; which was referred to the Committee on Energy and
Commerce
_______________________________________________________________________
A BILL
To amend the Comprehensive Addiction and Recovery Act of 2016 to
authorize the Attorney General, in coordination with the Administrator
of the Drug Enforcement Administration, the Secretary of Health and
Human Services, and the Director of the Office of National Drug Control
Policy, to award grants to covered entities to establish or maintain
disposal sites for unwanted prescription medications, and for other
purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Safe Disposal of Opioids Act of
2026''.
SEC. 2. GRANTS FOR DISPOSAL SITES FOR UNWANTED PRESCRIPTION
MEDICATIONS.
Section 203 of the Comprehensive Addiction and Recovery Act of 2016
(21 U.S.C. 822a) is amended by adding at the end the following:
``(c) Grants for Disposal Sites for Unwanted Prescription
Medications.--
``(1) Grants.--
``(A) Awards.--In carrying out subsection (b), the
Attorney General shall award grants to covered entities
to establish or maintain disposal sites for unwanted
prescription medications.
``(B) Limitation.--Of the total amount of awards
under subparagraph (A) for a fiscal year, the Attorney
General shall not award more than 10 percent to covered
entities that are--
``(i) State, local, or tribal law
enforcement agencies; or
``(ii) manufacturers, distributors, or
reverse distributors of prescription
medications.
``(2) Discounts for eligible patients.--
``(A) In general.--The Secretary of Health and
Human Services shall establish a mechanism by which
amounts paid by an eligible patient for an active
opioid are discounted at time of payment or purchase to
ensure that such patient does not pay any amount
attributable to a fee under paragraph (3), with as
little burden on the patient as possible.
``(B) Definition.--For purposes of subparagraph
(A), the term `eligible patient' means--
``(i) a patient for whom any active opioid
(as so defined) is prescribed to treat pain
relating to cancer or cancer treatment;
``(ii) a patient participating in hospice
care; and
``(iii) in the case of the death or
incapacity of a patient described in clause (i)
or (ii) or any similar situation as determined
by the Secretary of Health and Human Services,
the appropriate family member, medical proxy,
or similar representative or the estate of such
patient.
``(3) Fees.--
``(A) In general.--There is hereby imposed on the
sale of any active opioid by the manufacturer,
producer, or importer a fee equal to 1 cent per 100
milligrams so sold.
``(B) Special rules.--
``(i) Definition.--In this paragraph, the
term `active opioid'--
``(I) means any controlled
substance (as defined in section 102 of
the Controlled Substances Act, as in
effect on the date of the Safe Disposal
of Opioids Act of 2026) which is opium,
an opiate, or any derivative thereof;
and
``(II) excludes any prescribed drug
which is used exclusively for the
treatment of opioid addiction as part
of a medically assisted treatment
effort.
``(ii) Exclusion of other ingredients.--In
the case of a product that includes an active
opioid and another ingredient, subparagraph (A)
shall apply only to the portion of such product
that is an active opioid.
``(4) Authorization of appropriations.--For fiscal year
2027 and each subsequent fiscal year, there is authorized to be
appropriated to carry out this subsection an amount not to
exceed the aggregate amount of the fees collected pursuant to
paragraph (3).''.
<all>